)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Precision BioSciences (DTIL) investor relations material
Precision BioSciences Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary3 Nov, 2025
Executive summary
Report covers the quarter ended September 30, 2025, for a clinical-stage gene editing company focused on in vivo therapies using the ARCUS platform.
Key programs include PBGENE-HBV (Hepatitis B) in Phase 1 and PBGENE-DMD (Duchenne muscular dystrophy) preparing for IND filing, with new clinical and preclinical data presented.
Initiated dosing in Cohort 3 of the ELIMINATE-B Phase 1 trial for chronic hepatitis B, with additional data readouts planned for early 2026.
Novartis terminated its collaboration agreement effective January 2026; milestone payment received from Imugene.
Cost reduction initiatives and operating efficiencies implemented in Q3 2025 to extend cash runway into the second half of 2027.
Financial highlights
Revenue for Q3 2025 was $13,000, down from $576,000 in Q3 2024; nine-month revenue was $60,000, down from $68.1 million in 2024, mainly due to prior period milestone and license revenue.
Net loss for Q3 2025 was $21.8 million ($1.84 per share), compared to $16.4 million ($2.25 per share) in Q3 2024; nine-month net loss was $65.9 million.
Operating expenses for Q3 2025 were $20.7 million, down slightly from $21.9 million in Q3 2024.
Cash, cash equivalents, and restricted cash totaled $71.2 million as of September 30, 2025, compared to $121.3 million a year earlier.
Accumulated deficit reached $548.3 million as of September 30, 2025.
Outlook and guidance
Cash runway expected to fund operations into the second half of 2027, supporting potential Phase 2 for PBGENE-HBV and pivotal study for PBGENE-DMD.
Phase 1 initiation for PBGENE-DMD anticipated in H1 2026, with initial data expected in H2 2026.
Additional data readouts for PBGENE-HBV planned in early 2026.
Data from the OTC-HOPE trial (partnered program) expected in H1 2026.
What HBsAg reduction is needed for a functional cure?
How does PBGENE-DMD address >60% of DMD patients?
What additional CART transactions are expected?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Precision BioSciences earnings date
Q4 202527 Mar, 2026
Next Precision BioSciences earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Precision BioSciences Inc. is a U.S.-based biotechnology company focused on developing gene editing technologies. The company utilizes its proprietary ARCUS genome editing platform to research and develop treatments for genetic disorders and cancers. Its work spans cell and gene therapies, with applications in both in vivo and allogeneic CAR T-cell therapies. Precision BioSciences collaborates with academic institutions and pharmaceutical companies to advance its research and clinical programs. The company is headquartered in Durham, North Carolina, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage